letaplimab

Letaplimab is a fully human IgG4 monoclonal antibody that targets CD47, a cell surface protein overexpressed on many cancer cells. By binding to CD47, letaplimab blocks its interaction with signal-regulatory protein alpha (SIRPα) on macrophages, thereby inhibiting the "don't eat me" signal and promoting phagocytosis of tumor cells. This mechanism enhances anti-tumor immune responses through both direct macrophage-mediated phagocytosis and T lymphocyte stimulation. Letaplimab has demonstrated preclinical efficacy in models of non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML), both as monotherapy and in combination with azacitidine. It is being developed primarily for hematologic malignancies such as AML, myelodysplastic syndromes (MDS), and lymphoma by Innovent Biologics[3][5][6].

Other names

human anti-CD47 monoclonal antibody